Low-risk prostate cancer: to treat or not to treat
Mené en Europe sur 413 patients atteints d'un cancer de la prostate à faible risque, cet essai multicentrique de phase III évalue l'efficacité et la toxicité d'une thérapie photodynamique (à base de padéliporfine administrée par voie intraveineuse et de fibres optiques) ciblant la vascularisation tumorale (durée médiane de suivi : 24 mois)
The risk of death and cancer-related morbidity for most men with low-risk prostate cancer is very low.1 This finding has created interest in active surveillance,2 a management strategy by which the tumour is watched closely without initial intervention. Men are monitored closely so that those who unknowingly harbour more aggressive disease can selectively be treated while sparing most men from treatment-related impairments of urinary, sexual, and bowel function. However, are there treatments that provide good tumour control with reduced side-effects so that upfront treatment of all men makes sense?
The Lancet Oncology , commentaire, 2015